Androxal

Basic Androxal information

• INN (international nonproprietary name): Enclomifene, also spelled enclomiphene
• Brand names available in the United Kingdom: none (Androxal® is the intended brand name for enclomifene and is not licensed in the UK)
• ATC code: No ATC code assigned
• Forms and dosages: investigational oral tablets; commonly studied strengths were 12.5 mg and 25 mg
• Manufacturers in the United Kingdom: no licensed UK manufacturer
• Registration status in the United Kingdom: Not licensed in the UK
• OTC / Rx classification: Not licensed in the UK; investigational (prescription-only in trial settings); not available over the counter

What Androxal is

The name is important, but so is the category behind it.

Androxal is the intended brand for enclomifene, with EnCyzix noted as a tentative former name.

INN and alternative spelling

INN: enclomifene.

Alternative spelling: enclomiphene.

Brand development and discontinued status

Androxal® was the intended brand name, but it is not commercially available.

Packaging was expected as oral tablets, usually with enclomifene citrate formulation, but commercial packaging data is not available because development was discontinued.

Drug class and mechanism category

Enclomifene is a nonsteroidal selective oestrogen receptor modulator, or SERM.

More specifically, it acts as an investigational oestrogen receptor antagonist and gonadotropin stimulant for male hypogonadism.

That distinction matters for patients comparing clomiphene, tamoxifen, and testosterone replacement therapy.

Definition list

INN

Enclomifene, also spelled enclomiphene.

Brand name

Androxal®.

Class

Nonsteroidal SERM.

Status

Experimental and not approved for routine medical use.

Regulatory status in the UK: why it is not prescribed on the NHS

The practical point is simple: Androxal is not available on the NHS because it is not licensed for routine use.

It has not been approved for routine use, so there is no standard regulated supply for UK prescribers to work from.

A GP cannot simply issue it like a standard licensed medicine.

Private clinics may discuss related hormone options, but Androxal itself remains outside normal prescribing pathways.

MHRA and UK prescribing reality

There is no public evidence of MHRA approval, and no active prescription status in the UK.

That means UK pharmacy advice is focused on lawful, regulated alternatives rather than trying to source enclomifene directly.

What “not approved” means for patients

It means there is no approved patient leaflet, no standard NHS supply route, and no over-the-counter option.

It also means a private prescription service cannot treat Androxal as a routine medicine.

For patients, the result is usually a referral conversation rather than a straightforward sale.

Symptoms, fertility concerns and treatment expectations

A man may have low energy, reduced libido, poor mood, or fertility worries and be looking for low testosterone support.

The appeal is obvious: it may stimulate endogenous testosterone rather than replace it externally.

Men looking for testosterone support

That matters to men who want treatment for male hypogonadism without moving straight to TRT.

Some want a hormone-related option that fits daily life and does not involve injections or gel.

Fertility-Preserving alternatives

Many patients are also trying to preserve fertility.

That is why clomifene, clomifene citrate, and other men’s health clinic discussions often come up before TRT is chosen.

A pharmacist would usually frame this as a consultation problem, not a self-selection problem.

How Androxal works: mechanism of action in plain English

At its core, enclomifene is the active (E)-isomer of clomiphene.

It works by blocking oestrogen feedback at the hypothalamus, which can increase LH and FSH secretion.

In men, that may promote the body’s own testosterone production.

Blocking oestrogen feedback

The hypothalamus helps regulate hormone signals by reading feedback from oestrogen.

When that feedback is blocked, the body may respond by increasing hormone signalling through the reproductive axis.

LH and FSH stimulation

LH and FSH are gonadotropins.

Raising them is the reason enclomifene was investigated in male hypogonadism and male infertility secondary to low testosterone.

Why testosterone may rise

This is the key distinction versus TRT.

TRT supplies testosterone directly, while enclomifene was studied to encourage endogenous testosterone production.

That can affect fertility expectations, side-effect concerns, and long-term treatment planning.

Simple flow: oestrogen feedback blocked → LH and FSH rise → testes are stimulated → testosterone production may increase.

Forms and dosage strengths: what was studied

Androxal is not approved or commercially available anywhere as of 2025.

What exists is trial information, not normal pharmacy stock.

Who developed Androxal

Repros Therapeutics Inc. was the original sponsor and developer.

There are no licensed generic or branded manufacturers because the medicine never achieved approval.

That is the main reason legitimate pharmacy stock does not exist.

Standard doses reported in trials and why they cannot be self-prescribed

Trial regimens for male secondary hypogonadism commonly used 12.5 mg to 25 mg orally once daily.

That is clinical-trial dosing only, not a user instruction.

No approved patient leaflet exists because the product is not licensed.

Children have not been studied, elderly data are not established, and no dosing recommendations exist for liver or kidney impairment.

Self-dosing is risky; a registered pharmacist would generally advise against unsupervised hormone products and direct the patient to a GP or specialist service.

Safety profile: common side effects and what patients report most often

Like any hormone-related medicine, the main concern for patients is not only whether it works, but how it feels day to day.

Because Androxal is not licensed, the side-effect profile comes from limited studies rather than long-term routine use.

Mild to moderate adverse effects

• Headache.
• Nausea.
• Visual disturbances, including blurred vision or spots.
• Hot flushes.
• Mood changes.

Visual symptoms and mood changes

Visual symptoms deserve particular attention.

Even a mild blur can affect driving, screen work, or a normal work shift.

Mood changes can also be unsettling when a person is already dealing with fatigue, low testosterone, or fertility stress.

When side effects need urgent review

Seek medical review quickly if visual symptoms appear, worsen, or do not settle.

Any significant change in mood or well-being should also be discussed before continuing a hormone-related product.

Contraindications and high-risk situations: who should avoid it

These are not theoretical labels.

They are the reasons formal medical assessment is needed before any hormone-related therapy is considered.

If a person has a history of thrombosis, liver disease, renal impairment, or hormone-dependent cancer, an unregulated supply is especially poor practice.

Dosage adjustments, missed doses and overdose: what the available guidance says

There is no robust adjustment guidance because the medicine was not developed into a routine licensed product.

That leaves limited practical advice from trials and investigational protocols.

Children and older adults

Children have not been studied.

Elderly data are not established.

No dosing recommendation is available for liver or kidney impairment.

Missed dose advice

Take the dose when remembered, unless it is close to the next scheduled dose.

Do not double up.

Overdose support only

No established antidote exists.

Supportive care is recommended.

Storage and handling

Storage guidance for investigational enclomifene is straightforward.

Keep it at room temperature, between 15 and 30°C, in the original packaging, and protect it from moisture.

This guidance is theoretical because there is no legal commercial pack in normal circulation.

Alternatives available in the UK

When Androxal comes up in clinic, the real comparison usually starts with clomifene citrate.

That is because clomiphene products such as Clomid and Serophene are more established and have broader clinical use.

Tamoxifen may also enter the conversation in some settings, and TRT remains the direct hormone-replacement route.

Many patients are trying to balance symptom relief, fertility, and convenience, and should discuss the options with a GP or specialist.

Legal status and availability in the UK

Androxal is not licensed in the UK, so there is no NHS prescription route and no licensed over-the-counter supply.

In our online pharmacy, Androxal is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Delivery across the United Kingdom